Rxsight Inc (RXST)

$59.63

+2.93

(+5.17%)▲

Market is closed - opens 7 PM, 03 May 2024

Insights on Rxsight Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 30.66M → 28.58M (in $), with an average decrease of 6.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -17.67M → -9.17M (in $), with an average increase of 14.5% per quarter

Performance

  • $57.19
    $59.70
    $59.63
    downward going graph

    4.1%

    Downside

    Day's Volatility :4.21%

    Upside

    0.12%

    downward going graph
  • $18.09
    $59.63
    $59.63
    downward going graph

    69.66%

    Downside

    52 Weeks Volatility :69.66%

    Upside

    0.0%

    downward going graph

Returns

PeriodRxsight IncIndex (Russel 2000)
3 Months
27.69%
0.0%
6 Months
146.71%
0.0%
1 Year
216.34%
1.7%
3 Years
272.69%
-22.3%

Highlights

Market Capitalization
2.0B
Book Value
$4.44
Earnings Per Share (EPS)
-1.41
Wall Street Target Price
62.71
Profit Margin
-54.57%
Operating Margin TTM
-37.97%
Return On Assets TTM
-18.82%
Return On Equity TTM
-38.85%
Revenue TTM
89.1M
Revenue Per Share TTM
2.59
Quarterly Revenue Growth YOY
77.60000000000001%
Gross Profit TTM
21.3M
EBITDA
-46.0M
Diluted Eps TTM
-1.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.9
EPS Estimate Next Year
-0.71
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Rxsight Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5.17%

Current $59.63
Target $62.71

Company Financials

FY19Y/Y Change
Revenue
2.2M
-
Net Income
126.2M
-
Net Profit Margin
5.6K%
-
FY20Y/Y Change
Revenue
14.7M
↑ 554.98%
Net Income
27.6M
↓ 78.15%
Net Profit Margin
187.87%
↓ 5444.44%
FY21Y/Y Change
Revenue
22.6M
↑ 53.92%
Net Income
-48.7M
↓ 276.57%
Net Profit Margin
-215.5%
↓ 403.37%
FY22Y/Y Change
Revenue
49.0M
↑ 116.9%
Net Income
-66.8M
↑ 37.11%
Net Profit Margin
-136.22%
↑ 79.28%
FY23Y/Y Change
Revenue
89.1M
↑ 81.77%
Net Income
-48.6M
↓ 27.19%
Net Profit Margin
-54.57%
↑ 81.65%
Q3 FY22Q/Q Change
Revenue
12.6M
↑ 11.05%
Net Income
-17.7M
↑ 0.03%
Net Profit Margin
-140.13%
↑ 15.43%
Q4 FY22Q/Q Change
Revenue
16.1M
↑ 27.53%
Net Income
-15.6M
↓ 11.7%
Net Profit Margin
-97.03%
↑ 43.1%
Q1 FY23Q/Q Change
Revenue
17.5M
↑ 8.71%
Net Income
-14.8M
↓ 4.97%
Net Profit Margin
-84.82%
↑ 12.21%
Q2 FY23Q/Q Change
Revenue
20.8M
↑ 18.99%
Net Income
-13.8M
↓ 6.94%
Net Profit Margin
-66.33%
↑ 18.49%
Q3 FY23Q/Q Change
Revenue
30.7M
↑ 47.37%
Net Income
-12.4M
↓ 10.06%
Net Profit Margin
-40.48%
↑ 25.85%
Q4 FY23Q/Q Change
Revenue
28.6M
↓ 6.81%
Net Income
-9.2M
↓ 26.08%
Net Profit Margin
-32.11%
↑ 8.37%
FY19Y/Y Change
Total Assets
110.4M
-
Total Liabilities
415.0M
-
FY20Y/Y Change
Total Assets
100.7M
↓ 8.83%
Total Liabilities
398.2M
↓ 4.06%
FY21Y/Y Change
Total Assets
192.7M
↑ 91.43%
Total Liabilities
54.5M
↓ 86.32%
FY22Y/Y Change
Total Assets
150.2M
↓ 22.08%
Total Liabilities
60.3M
↑ 10.62%
FY23Y/Y Change
Total Assets
182.6M
↑ 21.57%
Total Liabilities
22.2M
↓ 63.18%
Q3 FY22Q/Q Change
Total Assets
155.7M
↓ 6.6%
Total Liabilities
59.7M
↑ 5.32%
Q4 FY22Q/Q Change
Total Assets
150.2M
↓ 3.56%
Total Liabilities
60.3M
↑ 0.86%
Q1 FY23Q/Q Change
Total Assets
202.5M
↑ 34.87%
Total Liabilities
57.5M
↓ 4.55%
Q2 FY23Q/Q Change
Total Assets
195.3M
↓ 3.59%
Total Liabilities
38.1M
↓ 33.81%
Q3 FY23Q/Q Change
Total Assets
181.9M
↓ 6.87%
Total Liabilities
20.4M
↓ 46.49%
Q4 FY23Q/Q Change
Total Assets
182.6M
↑ 0.38%
Total Liabilities
22.2M
↑ 8.92%
FY19Y/Y Change
Operating Cash Flow
-40.6M
-
Investing Cash Flow
-5.9M
-
Financing Cash Flow
1.3M
-
FY20Y/Y Change
Operating Cash Flow
-35.2M
↓ 13.33%
Investing Cash Flow
15.6M
↓ 365.6%
Financing Cash Flow
25.2M
↑ 1797.52%
FY21Y/Y Change
Operating Cash Flow
-44.7M
↑ 27.0%
Investing Cash Flow
-81.9M
↓ 625.35%
Financing Cash Flow
137.3M
↑ 444.21%
FY22Y/Y Change
Operating Cash Flow
-58.9M
↑ 31.63%
Investing Cash Flow
40.0M
↓ 148.77%
Financing Cash Flow
6.3M
↓ 95.39%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.2M
↑ 2.46%
Investing Cash Flow
560.0K
↓ 96.04%
Financing Cash Flow
-455.0K
↓ 178.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.9M
↓ 8.78%
Investing Cash Flow
10.4M
↑ 1758.04%
Financing Cash Flow
6.3M
↓ 1486.15%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.8M
↑ 28.22%
Investing Cash Flow
-48.4M
↓ 564.82%
Financing Cash Flow
65.3M
↑ 935.44%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.5M
↓ 57.52%
Investing Cash Flow
4.4M
↓ 109.09%
Financing Cash Flow
891.0K
↓ 98.64%

Technicals Summary

Sell

Neutral

Buy

Rxsight Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rxsight Inc
Rxsight Inc
16.37%
146.71%
216.34%
272.69%
272.69%
Stryker Corporation
Stryker Corporation
-6.94%
18.25%
13.75%
24.15%
71.27%
Boston Scientific Corp.
Boston Scientific Corp.
5.72%
37.12%
36.71%
65.09%
93.63%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.56%
26.82%
-3.45%
-10.11%
40.59%
Abbott Laboratories
Abbott Laboratories
-4.82%
10.52%
-5.23%
-11.39%
34.6%
Medtronic Plc
Medtronic Plc
-4.8%
11.52%
-10.77%
-38.32%
-9.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rxsight Inc
Rxsight Inc
NA
NA
NA
-0.9
-0.39
-0.19
NA
4.44
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.58
37.58
5.19
2.75
0.21
0.12
NA
11.83
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rxsight Inc
Rxsight Inc
Buy
$2.0B
272.69%
NA
-54.57%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
71.27%
40.83
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
93.63%
68.14
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.0B
40.59%
37.58
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
34.6%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.67%
25.52
13.0%

Institutional Holdings

  • RA Capital Management, LLC

    9.20%

  • Artisan Partners Limited Partnership

    6.48%

  • BlackRock Inc

    5.61%

  • Lord, Abbett & Co LLC

    5.35%

  • Vanguard Group Inc

    4.01%

  • FMR Inc

    3.21%

Company Information

calhoun vision is the world leader in adjustable intraocular lens technology. the company's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted in the eye. this offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient. calhoun vision's light adjustable lens technology is an investigational device in the united states and requires fda approval before it can be marketed commercially. the company has completed phases i and ii of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled.

Organization
Rxsight Inc
Employees
374
CEO
Dr. Ronald M. Kurtz M.D.
Industry
Miscellaneous

Discover More

FAQs